What You Should Know
- Updated long-term data from the RUBY trial apply cure modeling to dMMR/MSI-H advanced endometrial cancer, suggesting a meaningful proportion of patients — in the mid-50% range — may achieve prolonged, treatment-free survival consistent with durable disease control.
- The emerging plateau in the dMMR/MSI-H survival curve is consistent with sustained immune surveillance in tumors where high immunogenicity makes them particularly sensitive to PD-1 blockade; dostarlimab may amplify chemotherapy-induced antigen release, enabling long-term remission in a subset of patients.
- “Cure modeling” describes the statistical shape of the survival curve — not individual certainty of disease eradication — an important distinction for clinicians discussing outcomes with patients.
- Key questions remain open: durability beyond current follow-up, optimal sequencing at relapse for patients in the potential curative fraction, and late immune-related effects — but the RUBY signal represents a genuine shift in how long-term outcomes are being conceptualized in this disease.
Survival curves in advanced endometrial cancer do not usually plateau. However, at ASCO 2026, the RUBY long-term analysis showed a survival curve that does, and the field is now having a conversation it has rarely had in this disease.
The updated long-term analysis from the RUBY trial, presented as ASCO Abstract 5501, adds an important perspective to the evolving treatment landscape in mismatch repair-deficient (dMMR) endometrial cancer. Beyond the established survival benefit, investigators explored whether a subset of patients may experience outcomes consistent with durable remission, or what cure-modeling analyses describe as a potential “curative fraction.”
A Plateauing Curve
RUBY previously demonstrated that adding dostarlimab to carboplatin and paclitaxel significantly improves outcomes in advanced or recurrent endometrial cancer, with the greatest benefit seen in the dMMR/MSI-H subgroup.
The updated analysis applied cure-modeling approaches to long-term survival data and estimated that approximately 54% of patients in the dMMR cohort may achieve prolonged disease control, compared with 14% of patients treated with chemotherapy alone. This represents a notable shift in how clinicians think about advanced endometrial cancer.
Historically, recurrent or metastatic disease has been viewed as relapsing and incurable, even among patients with MSI-H tumors. The RUBY data suggest that adding PD-1 blockade to chemotherapy may alter the trajectory for a subset of patients, with survival curves showing an emerging plateau, a hallmark often associated with long-term disease control in immunotherapy-responsive cancers.
Dr. Sarah Lynam, a gynecologic oncologist at University Hospitals in Cleveland, Ohio.
“Historically, survival had been very poor for patients who have recurrent endometrial cancer,” said Dr. Sarah Lynam, a gynecologic oncologist at University Hospitals in Cleveland, Ohio.
“These studies demonstrate that there is a significant proportion of patients who actually will benefit and can potentially be cured with the use of this therapy, which is something that we haven’t been able to say in advanced endometrial cancer before.”
Importantly, cure modeling does not prove eradication of disease or establish a definitive cure rate. Rather, it estimates the proportion of patients whose risk of progression appears to stabilize over time. The findings are consistent with the biology of dMMR/MSI-H tumors, which are particularly sensitive to immune checkpoint blockade.
Clinically, RUBY reinforces that mismatch repair status is not only predictive of response but may also identify patients with the greatest potential for durable benefit from frontline chemo-immunotherapy.
“We are talking about a cure in late-stage disease for the first time in advanced endometrial cancer,” Dr. Lynam noted.
Lingering Questions
Despite the promise, questions remain regarding long-term durability, optimal sequencing after relapse, and the impact of extended maintenance immunotherapy. Patients in RUBY received dostarlimab maintenance following chemotherapy, and ongoing follow-up will be needed to determine whether these outcomes persist over time.
Still, the RUBY Abstract 5501 update provides one of the strongest signals to date that frontline chemo-immunotherapy may be reshaping long-term outcomes in biologically selected dMMR/MSI-H endometrial cancer, moving a subset of patients closer to durable remission rather than repeated relapse.
